NPR, July 19, 2018
Alison Kodjak


Listen to the Full Story

Louisiana is working with Gilead Sciences and other companies on a deal that would change how the state pays for expensive hepatitis C drugs, with the goal of eliminating the disease in that state.

health care finance infectious diseases market pharmaceuticals public health regulation